AstraZeneca completes equity investment in Summit
5 October 2026 AstraZeneca completes equity investment in Summit Therapeutics AstraZeneca today announced the successful completion of its $2 billion equity investment in Summit Therapeutics....
Company profile
AstraZeneca PLC
Pipeline32 assets
- camizestrant + CDK4/6ingSERD + CDK4/6i / small molecule combination / Oncology1L HR+ HER2- ESR1m advanced breast cancerPhase IIISubmitted
- camizestrant + palbociclibngSERD + CDK4/6i / small molecule combination / Oncology1L HR+ HER2- advanced breast cancerPhase III
- camizestrant +/- abemaciclibngSERD + CDK4/6i / small molecule combination / Oncologyadjuvant HR+ HER2- early breast cancerPhase III
- camizestrantngSERD / small molecule / Oncologyadjuvant switch HR+ HER2- early breast cancerPhase III
- AZD0120AZD0120 / CD19/BCMA CAR-T / cell therapy / Oncology/Rare Disease/Respiratory & Immunologyrelapsed/refractory multiple myelomaPhase IIINew to Phase IIIamyloid light-chain amyloidosisPhase Isystemic lupus erythematosusPhase I
- puxitatug samrotecanB7-H4 TOP1i ADC / antibody-drug conjugate / Oncology2-3L B7-H4+ endometrial cancerPhase III
- rilvegostomigPD-1/TIGIT bispecific mAb / bispecific antibody / OncologyHCC; biliary tract; NSCLC; gastric cancerPhase III
- saruparibPARP1 inhibitor / small molecule / Oncologyprostate cancer; breast cancerPhase III
- sonesitatug vedotinCLDN18.2 MMAE ADC / antibody-drug conjugate / OncologyCLDN18.2+ gastric cancerPhase III
- surovatamigAZD0486 / CD19/CD3 T-cell engager / bispecific antibody / Oncology/Respiratory & Immunology1L elderly DLBCL; follicular lymphomaPhase IIIB-cell driven autoimmune diseasePhase I
- torvutatug samrotecanAZD5335 / anti-FRα TOP1i ADC / antibody-drug conjugate / Oncologyovarian cancerPhase III
- volrustomigPD-1/CTLA-4 bispecific mAb / bispecific antibody / Oncologycervical cancer; HNSCC; NSCLC; mesotheliomaPhase IIIcolorectal cancer; NSCLC; other solid tumoursPhase II
- balcinrenone/dapagliflozinMR antagonist/modulator + SGLT2 inhibitor / small molecule combination / Cardiovascular, Renal and Metabolismheart failure with CKDPhase IIICKDPhase II
- baxdrostataldosterone synthase inhibitor / small molecule / Cardiovascular, Renal and MetabolismhypertensionPhase IIIAcceptedprimary aldosteronismPhase III
- baxdrostat/dapagliflozinaldosterone synthase inhibitor + SGLT2 inhibitor / small molecule combination / Cardiovascular, Renal and MetabolismCKD; prevention of heart failurePhase III
- laroprovstatPCSK9 inhibitor / small molecule / Cardiovascular, Renal and MetabolismdyslipidaemiaPhase III
- WainuaWainua / ligand-conjugated antisense / antisense oligonucleotide / Cardiovascular, Renal and MetabolismATTRv-PNPhase IIILaunchedATTR CMLCM
- zibotentan/dapagliflozinendothelin A receptor antagonist/SGLT2 inhibitor / small molecule combination / Cardiovascular, Renal and MetabolismCKD with high proteinuriaPhase III
- elecoglipronoral GLP-1 receptor agonist / small molecule / Cardiovascular, Renal and MetabolismT2D/chronic weight managementPhase II
- AZD6234AZD6234 / peptide / peptide / Cardiovascular, Renal and Metabolismchronic weight management in overweight or obesityPhase II
- tozorakimabIL-33 mAb / monoclonal antibody / Respiratory & ImmunologyCOPDPhase IIIsevere viral lower respiratory tract diseasePhase IIIasthmaPhase II
- TezspireTezspire / TSLP mAb / monoclonal antibody / Respiratory & Immunologysevere uncontrolled asthmaPhase IIILaunchedChinaeosinophilic esophagitis; COPD; nasal polypsLCM
- SaphneloSaphnelo / type I IFN receptor mAb / monoclonal antibody / Respiratory & Immunologysystemic lupus erythematosusPhase IIILaunchedChinacutaneous lupus erythematosus; SLE SCLCM
- anselamimabfibril-reactive mAb / monoclonal antibody / Rare Diseaseamyloid light-chain amyloidosisPhase IIISubmitted
- cliramitugtransthyretin depleter / large molecule / Rare Diseasetransthyretin amyloid cardiomyopathyPhase III
- efzimfotase alfanext generation TNSALP ERT / enzyme replacement therapy / Rare DiseasehypophosphatasiaPhase III
- eneboparatideparathyroid hormone receptor 1 / large molecule / Rare DiseasehypoparathyroidismPhase III
- gefurulimabanti-C5 dual-binding nanobody / nanobody / Rare Diseasegeneralised myasthenia gravisPhase IIISubmitted
- KavigaleKavigale / SARS-CoV-2 LAAB / long-acting antibody / Infectious Diseaseprevention of COVID-19Phase IIILaunched
- AZD0292AZD0292 / pseudomonas Psl-PcrV bispecific mAb / bispecific antibody / Infectious DiseasebronchiectasisPhase II
- AZD5148AZD5148 / anti-Clostridioides difficile TcdB mAb / monoclonal antibody / Infectious Diseasereduction of C. diff recurrencePhase II
- AZD7760AZD7760 / S. aureus virulence factors / mAb combination / Infectious Diseaseprevention of Staph aureus infectionPhase II
Latest news25 items
All newsAZ & DS collaboration with Summit for Datroway
02 October 2026 AstraZeneca and Daiichi Sankyo announce clinical collaboration with Summit Therapeutics to evaluate Datroway in combination with ivonescimab across multiple tumour types Builds on recently announced clinical collaboration between AstraZeneca and Summit to advance leading ADC combination strategy in cancer AstraZeneca and Daiichi Sankyo have...
Admission of Further Securities to Trading
1 October 2026 Notification of Admission of Further Securities to Trading (PRM 1.6.4R) The following notification is made in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R....
Total Voting Rights
1 October 2026 Total Voting Rights The following notification is made in accordance with the UK Financial Conduct Authority’s Disclosure and Transparency Rule 5.6.1. As at 30 September 2026 the issued share capital of AstraZeneca PLC with voting rights is 1,551,053,289 ordinary shares of US$0.25. No shares are held in Treasury....
AstraZeneca announces equity investment in Summit
29 September 2026 AstraZeneca announces strategic equity investment and clinical collaboration with Summit Therapeutics to advance leading ADC combination strategy in cancer Clinical collaboration will evaluate sonesitatug vedotin, a Claudin-18.2 ADC, with ivonescimab, a first-in-class PD-1/VEGF bispecific, in gastrointestinal cancers Planned broader...
Trixeo approved in EU for asthma
23 September 2026 Trixeo approved in the EU for the maintenance treatment of asthma Trixeo is the first and only triple-combination therapy approved in the EU for patients 12 years and older, independent of exacerbation history AstraZeneca's fixed-dose triple-combination Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate or BGF...
Klygefa recommended for EU approval by CHMP
21 September 2026 Klygefa (gefurulimab) recommended for approval in the EU by CHMP for the treatment of adults with generalised myasthenia gravis (gMG) Recommendation based on PREVAIL Phase III trial demonstrating statistically significant and clinically meaningful improvement in Myasthenia Gravis Activities of Daily Living score If approved, Klygefa will...
Enhertu recommended for approval in EU in early BC
21 September 2026 Enhertu recommended for approval in the EU by CHMP as adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2-positive early breast cancer Based on DESTINY-Breast05 Phase III trial which showed Enhertu reduced the risk of invasive disease recurrence or death by 53% vs....
Director/PDMR Shareholding
18 September 2026 Transaction by Person Discharging Managerial Responsibilities AstraZeneca PLC (the Company) announces that it was notified on 16 September 2026 that Pascal Soriot, Chief Executive Officer of the Company, purchased 60,000 of the Company's ordinary shares of $0.25 each (Ordinary Shares) on 14 September 2026, as set out below....
Director/PDMR Shareholding
15 September 2026 Transaction by Person Discharging Managerial Responsibilities AstraZeneca PLC (the Company) announced that, on 14 September 2026, Dr Aradhana Sarin, Chief Financial Officer of the Company, acquired 73 of the Company's ordinary shares of $0.25 each (Ordinary Shares) following the vesting of certain dividend equivalent awards accrued in...
Director/PDMR Shareholding
15 September 2026 Transaction by Person Discharging Managerial Responsibilities AstraZeneca PLC (the Company) announces that it was notified on 14 September 2026 that Michel Demaré, Non-Executive Chair of the Board, purchased 2,500 of the Company's ordinary shares of $0.25 each (Ordinary Shares) on 14 September 2026, as set out below....
Update on SERENA-4 Phase III trial
This announcement contains inside information 14 September 2026 Update on SERENA-4 Phase III trial of Etcamah in combination with palbociclib in upfront 1st-line advanced ER-positive breast cancer SERENA-4 trial did not meet primary objective of statistically significant improvement in progression-free survival, however a numerical improvement was observed...
Trial Results • Phase 3SERENA-4 trial results Mon, Sep 14, 2026, 8:00 AM CET
Imfinzi+Imdelltra improved OS in small cell lung
8 September 2026 Imfinzi plus Imdelltra demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer Imfinzi is the first and only immunotherapy in combination with a bispecific T-cell engager to show survival benefit in this setting...
Trial Results • Phase 3Results event Tue, Sep 8, 2026
Etcamah approved in the US for HR+ breast cancer
07 September 2026 Etcamah in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer Approval based on SERENA-6 Phase III trial results which showed combination reduced the risk of disease progression or death by 56% in patients with an emergent ESR1 tumour mutation Innovative treatment strategy has potential...
Admission of Further Securities to Trading
1 September 2026 Notification of Admission of Further Securities to Trading (PRM 1.6.4R) The following notification is made in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R....
Total Voting Rights
1 September 2026 Total Voting Rights The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 August 2026 the issued share capital of AstraZeneca PLC with voting rights is 1,551,043,461 ordinary shares of US$0.25. No shares are held in Treasury....
Admission to Trading - €2.55 billion bond offering
1 September 2026 Admission to Trading - €2.55 billion bond offering In accordance with the Financial Conduct Authority's Prospectus Rules: Admission to Trading on a Regulated Market (PRM) sourcebook 1.5.2 and 1.5.3R, AstraZeneca PLC announces that its wholly owned subsidiary AstraZeneca Finance LLC notifies the market that debt securities have been admitted...
Enhertu approved in EU for 1L HER2-positive mBC
01 September 2026 Enhertuplus pertuzumab approved in the EU as first new regimen in more than a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer Based on DESTINY-Breast09 Phase III trial which showed AstraZeneca and Daiichi Sankyo's Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% vs....
Directorate change
1 September 2026 Non-Executive Board Appointment AstraZeneca PLC announced today that Wan Ling Martello has been appointed as Non-Executive Director with effect from 1 September 2026. Wan Ling will become a member of the Audit Committee on appointment to the Board....
AstraZeneca completes agreement for Zegfrovy
01 September 2026 AstraZeneca completes global license agreement for oral EGFR inhibitor Zegfrovy for lung cancer AstraZeneca today announced the successful completion of the previously announced exclusive license agreement (https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-licenses-novel-egfr-inhibitor.html) with Dizal Pharmaceutical...
Tagrisso + Orpathys improved PFS in 1L EGFRm lung
1 September 2026 Tagrisso plusOrpathysdemonstrated statistically significant and highly clinically meaningful improvement in progression-free survival in 1st-line MET-overexpressing EGFR-mutated lung cancer Results of SANOVO Phase III trial in China build on established success of global SAFFRON and China SACHI trials, extending clinical value of the...
Trial Results • Phase 3oral presentation Tue, Sep 1, 2026
Tezspire CROSSING trial met primary endpoints
27 August 2026 Tezspire demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints Statistically significant and clinically meaningful disease and symptom improvements compared to placebo maintained through week 52 Efficacy in a third epithelial-driven inflammatory disease supports broad...
Trial Results • Phase 3Results event Thu, Aug 27, 2026
AstraZeneca prices a €2.55 billion bond offering
25 August 2026 AstraZeneca prices €2.55 billion bond offering AstraZeneca PLC (the Company) announces that, on 24 August 2026, its wholly owned subsidiary AstraZeneca Finance LLC, successfully priced four tranches of Eurobonds totalling €2.55 billion (the Offering)....
Director/PDMR Shareholding
19 August 2026 Transaction by Person Discharging Managerial Responsibilities AstraZeneca PLC (the Company) announced that, on 17 August 2026, an award of the Company's ordinary shares of $0.25 each (Ordinary Shares) vested to the Company's Chief Financial Officer, Dr Aradhana Sarin, under the AstraZeneca Performance Share Plan (the AZPSP)....
Enhertu improved PFS in 1L HER2m lung cancer
17 August 2026 Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial AstraZeneca and Daiichi Sankyo's Enhertu is the first and only HER2-directed medicine to improve...
Trial Results • Phase 3Results event Mon, Aug 17, 2026